IDRA - Idera Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Idera Pharmaceuticals, Inc.

505 Eagleview Boulevard
Suite 212
Exton, PA 19341
United States

Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent J. MilanoPres, CEO & Director783.86kN/A1964
Mr. John J. KirbySr. VP & CFO347.39kN/A1972
Dr. Jonathan YinglingSr. VP of Early Devel. & Chief Scientific Officer513.93kN/A1969
Mr. Robert Clayton FletcherSr. VP of Bus. Devel. & Strategic Planning515.61kN/A1963
Dr. Joanna C. HorobinAdvisor532.09kN/A1955
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.

Corporate Governance

Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.